Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 0435 • ACR Convergence 2025
Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study
Ahmad Alomari¹, Reem Elmusa², Nikita Shah³, Miguel Rodriguez⁴ and Diala Alawneh⁵, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/ HCA - North florida hospital, Gainesville, FL, ³UCF/HCA Florida North Florida Hospital, Gainesville, FL, ⁴SIMED Rheumatology, Gainesville, FL, ⁵University of Florida, Gainesville, FL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 0173 • ACR Convergence 2025
Association Between the Ratio of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and All-Cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
Tingting Wang¹, Siying Xiong¹, Yuanli Wei¹, Dongmei Wang¹, Weihua Zhang¹, Caizhen Liu², Fanxin zeng³ and Jianhong Wu¹, ¹Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, China (People's Republic), ²Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, ³Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital; Medical School, Sichuan University of Arts and Sciences; School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Dazhou, China (People's Republic)
Background/Purpose: The Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio (NHHR) has emerged as a promising marker for atherosclerosis, yet its relationship with all-cause mortality…
Abstract Number: 0090 • ACR Convergence 2025
Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts
Marie Svenja Kümmel¹, Mona Arnold-Gräf², Selina Ohl², Klaus Frommer³, Nils Schulz⁴, Stefan Rehart⁵, Ulf Müller-Ladner³ and Elena Neumann³, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Gießen, Germany, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Germany, ³Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Hessen, Germany, ⁴Kerkchoff Klinik, Dep. of rheumatology, Bad Nauheim, Germany, ⁵Agaplesion Markus Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASF) play a central role in driving inflammation and promoting cartilage degradation in Rheumatoid arthritis (RA). In our study, we…
Abstract Number: 0071 • ACR Convergence 2025
Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
Chary López pedrera¹, Tomás Cerdó², Ismael Sanchez-Pareja², Daniel Toro³, MARIA ANGELES AGUIRRE ZAMORANO², Elena Moreno-Caño⁴, Laura muñoz-Barrera², Sagrario Corrales², Rafaela Ortega-Castro⁵, Concepción Aranda-Valera⁶, Lourdes Ladehesa⁷, Jerusalén Calvo⁶, Pilar Font⁸, M Carmen Abalos-Aguilera⁹, Desiree Ruiz-Vilchez¹⁰, Christian Merlo-Ruiz⁹, Nuria Barbarroja¹¹, Carlos Pérez Sánchez¹², Marta Alarcon-Riquelme¹³ and Alejandro Escudero Contreras⁶, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: This study aimed to identify shared and distinct gene and protein expression profiles associated with clinical features in rheumatoid arthritis (RA), systemic lupus erythematosus…
Abstract Number: 0048 • ACR Convergence 2025
Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting
Xue Wang¹, Fei Wang², Sílvia Sisó², Archana Iyer², Heather Knight², Lori Duggan², Yingli Yang², Liang Jin², Baoling Cui², Yupeng He³, Jan Schejbal², Lucy Phillips², Bohdan Harvey⁴ and Yu Tian², ¹AbbVie, South San Francisco, CA, ²AbbVie, Worcester, MA, ³AbbVie, North Chicago, IL, ⁴AbbVie, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Kathryne Marks¹, Alice Horisberger², Ifeoluwakiisi Adejoorin¹, Leah Santacroce¹, Mehreen Elahee³, Joan Bathon⁴, Kevin Wei⁵, Daniel Solomon⁶ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³Brigham and Women's Hospital, Wexford, PA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…
Abstract Number: 2564 • ACR Convergence 2025
An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
Mie Fusama¹, Hideko Nakahara², Megumi Okada³, Kayoko Sakagami⁴, Ikuyo Noguchi⁵, Harumi Matsumura⁶, Hiroaki Ito⁴, Kosaku Oda⁵, Yoshitaka Shinto³, Kenshi Higami⁶, Satomi Higami⁶ and Tetsuya Tomita⁷, ¹Kansai University of International Studies, Miki, Japan, ²Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, ³Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, ⁴Infusion Clinic, Osaka, Japan, ⁵Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, ⁶Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, ⁷Morinomiya University of Medical Sciences, Osaka, Japan
Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…
Abstract Number: 2260 • ACR Convergence 2025
Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
Shant Ayanian¹, Siavash Rezaei², Daniel Darveaux³, Marc Blasi³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Cerebras, Santa Clara, CA, ³Mayo Clinic, Rochester
Background/Purpose: Clinical notes typically contain a valuable trove of information which is rarely used in predictive modeling given the complexity of working with unstructured data.…
Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Yao-Wei Zou, Ying Yang, Zhi-Ming Ouyang, Ran Shi, Tao Wu, Kui-Min Yang, Jian-Da Ma and Lie Dai, Department of Rheumatology and Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic)
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…
Abstract Number: 2227 • ACR Convergence 2025
The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
Amir Razmjou¹, Rong Guo², David Elashoff², Kevin Deane³, Jill Norris⁴, Marie Feser⁵, Lauren Vanderlinden⁶, Jennifer Wang⁷, Ani Shahbazian⁷ and Christina Charles-Schoeman⁸, ¹UCLA / Veterans Affairs, Los Angeles, CA, ²UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, ³University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁴Colorado School of Public Health, Denver, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado Anschutz Medical Campus, Monument, CO, ⁷UCLA, Los Angeles, ⁸UCLA Medical Center, Santa Monica, CA
Background/Purpose: Rheumatoid arthritis (RA) has a pre-clinical state. In particular, elevation of antibodies to citrullinated proteins (ACPA) is a strong risk factor for future clinically-apparent…
Abstract Number: 1968 • ACR Convergence 2025
Relationship between ultrasonographic and elastographic findings of the median nerve and disease activity and hand function in patients with rheumatoid arthritis
Gulperi ISAZADE KASIMZADE¹, Ismihan Sunar², Sebnem ATAMAN³ and Aysun GENC¹, ¹Ankara University School of Medicine, Physical Medicine and Rehabilitation, Ankara, Turkey, ²Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology, Ankara, Turkey, ³Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune joint disease with systemic involvement which can affect the nerves through either compressive pathology due to intra-articular synovitis…
Abstract Number: 1893 • ACR Convergence 2025
Increased Atrial Fibrillation Risk in Rheumatoid Arthritis: Greater in Seropositive Than Seronegative Patients
Hyungjin Kim¹, Seonyoung Kang², Kyungdo Han³, Jinhyung Jung⁴, Seulkee Lee⁵, Hoon-Suk Cha⁵, Jaejoon Lee⁶, Seonghye Kim⁵ and Se Yun Kim⁷, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea, ⁴Sungkyunkwan University School of Medicine, Suwon, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁷Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: The association between rheumatoid arthritis (RA) and cardiovascular disease (CVD) is well-established, with systemic inflammation as a potential mechanism. Although atrial fibrillation (AF) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].